Pidnarulex

Generic Name: Pidnarulex

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₂₇N_₇O_₂S

CAS Number: 1138549-36-6

Unique Ingredient Identifier: 3R4C5YLB9I

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers

Phase 1

Not yet recruiting

Conditions: Metastatic Malignant Solid Neoplasm

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Biological: Pidnarulex

First Posted Date: 2024-09-23

Last Posted Date: 2024-09-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT06606990

Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer

Phase 1

Suspended

Conditions: Metastatic Castration Resistant Prostate Cancer (mCRPC)

Interventions: Drug: Pidnarulex
Drug: Talazoparib

First Posted Date: 2022-06-21

Last Posted Date: 2023-12-11

Lead Sponsor: Peter MacCallum Cancer Centre, Australia

Target Recruit Count: 48

Registration Number: NCT05425862

Locations: 🇦🇺
St Vincent's Hospital Sydney, Sydney, New South Wales, Australia
🇦🇺
Box Hill Hospital, Box Hill, Victoria, Australia
🇦🇺
Royal Melbourne Hospital, Melbourne, Victoria, Australia

and more 2 locations

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy